Ezetimibe

證據等級: L5

預測適應症: 4 個

Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia

One-Sentence Summary

Ezetimibe is a selective intestinal cholesterol absorption inhibitor, globally established as a key lipid-lowering agent for hypercholesterolemia, though it has not yet obtained market registration in Taiwan. The TxGNN model predicts it may be effective for Hyperlipoproteinemia — encompassing mixed hyperlipidemia with elevated LDL-cholesterol and triglycerides — with 50 clinical trials and 19 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Hypercholesterolemia (established global indication; no TFDA registration record available)
Predicted New Indication	Hyperlipoproteinemia
TxGNN Prediction Score	99.63%
Evidence Level	L1
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein at the intestinal brush border, blocking the reabsorption of both dietary and biliary cholesterol. This mechanism reduces intestinal cholesterol absorption by approximately 50%, which lowers hepatic cholesterol stores, triggers compensatory upregulation of LDL receptors (LDL-R), and ultimately decreases plasma LDL-C by 15–20% as monotherapy. When combined with a statin — which inhibits cholesterol synthesis via HMG-CoA reductase — the additive effect yields a further 15–20% LDL-C reduction, making Ezetimibe particularly valuable for patients unable to reach lipid targets on statin monotherapy alone. This NPC1L1/LDL-R axis is the core mechanistic rationale underlying all evidence presented below.

Hyperlipoproteinemia is a broad diagnostic category defined by pathologically elevated blood lipoproteins, encompassing mixed hyperlipidemia (raised LDL-C plus raised triglycerides; Type IIb), primary hypercholesterolemia (Type IIa), and genetic subtypes such as heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH). Ezetimibe's intestinal absorption-blocking mechanism directly targets the elevated LDL-C component shared across all these subtypes, while its combination with fenofibrate has been explicitly trialled in mixed dyslipidemia patients with elevated both LDL-C and triglycerides — precisely the population captured by "hyperlipoproteinemia." The TxGNN prediction score of 99.63% reflects this strong mechanistic and clinical alignment.

The evidence base is exceptionally robust by repurposing standards: multiple large-scale completed Phase 3 RCTs directly evaluate Ezetimibe as the primary intervention or active comparator across the hyperlipoproteinemia spectrum, and the drug is embedded as a standard second-line agent in ESC/EAS, ACC/AHA, and Japanese lipid guidelines. The current gap — no Taiwan TFDA registration — reflects a regulatory rather than a scientific uncertainty.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00093899	Phase 3	Completed	611	Large-scale RCT evaluating efficacy and safety of Ezetimibe/Simvastatin in combination with fenofibrate in patients with mixed hyperlipidemia (elevated cholesterol and triglycerides); highest-grade direct evidence for the hyperlipoproteinemia indication
NCT01763827	Phase 3	Completed	615	Double-blind, randomized, placebo- and ezetimibe-controlled trial evaluating 12 weeks of evolocumab monotherapy; ezetimibe served as the primary active comparator for LDL-C lowering in hypercholesterolemic adults
NCT01043380	Phase 4	Completed	245	IVUS (Plaque REgression study): head-to-head comparison of cholesterol absorption inhibitor (ezetimibe) vs. cholesterol synthesis inhibitor on coronary plaque regression; provides clinically meaningful surrogate endpoint data
NCT00092573	Phase 3	Completed	587	Evaluated cholesterol-lowering safety and effectiveness of fenofibrate + ezetimibe coadministration in patients with mixed hyperlipidemia; direct evidence for combination approach in Type IIb dyslipidemia
NCT00552097	Phase 3	Completed	720	ENHANCE Trial: Ezetimibe + high-dose simvastatin vs. simvastatin alone on carotid intima-media thickness (CIMT) progression in HeFH subjects; landmark carotid imaging RCT
NCT00349284	Phase 3	Completed	181	Double-blind RCT comparing fenofibrate 145 mg, ezetimibe 10 mg, and their combination in patients with Type IIb dyslipidemia and metabolic syndrome; directly addresses the lipid triad (elevated TG, LDL-C, low HDL-C)
NCT06005597	Phase 3	Completed	407	Placebo-controlled RCT of obicetrapib 10 mg + ezetimibe 10 mg fixed-dose combination on top of maximally tolerated lipid therapy in HeFH and/or ASCVD patients; recent evidence for ezetimibe in combination strategies
NCT03884452	Phase 3	Completed	50	Efficacy and safety study of ezetimibe (SCH58235) 10 mg added to atorvastatin or simvastatin in homozygous familial hypercholesterolemia; foundational Phase 3 trial establishing ezetimibe's FH evidence base
NCT00092833	Phase 3	Terminated	49	Treatment-use study providing ezetimibe 10 mg/day to HoFH and sitosterolemia patients; despite termination, provides mechanistic and safety reference data for severe hyperlipoproteinemia
NCT04433533	Phase 4	Unknown	200	Randomized head-to-head study comparing rosuvastatin/ezetimibe combination vs. rosuvastatin monotherapy in Korean patients with LV diastolic dysfunction and hyperlipidemia; real-world combination therapy evaluation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40347969	2025	Phase 2/3 RCT	Lancet	TANDEM trial: fixed-dose combination of obicetrapib (CETP inhibitor) and ezetimibe 10 mg demonstrated significant LDL-C reduction vs. placebo in patients with hypercholesterolemia on background statin therapy
41206969	2026	Phase 3 RCT	JAMA	Oral PCSK9 inhibitor enlicitide RCT in HeFH; highlights persistent unmet need where ezetimibe is standard background therapy and benchmark for LDL-C lowering
23956253	2013	Guideline/Consensus	European Heart Journal	EAS consensus on familial hypercholesterolemia: formally establishes ezetimibe as the recommended second-line lipid-lowering agent in combination with statins for coronary heart disease prevention
25939291	2015	Review	Cardiology Clinics	Comprehensive FH review listing ezetimibe alongside statins, bile acid sequestrants, and LDL apheresis as evidence-based treatment options; early treatment reduces cardiovascular events
29219151	2017	Review	Nature Reviews Disease Primers	Disease primer on familial hypercholesterolaemia covering genetics (LDLR, APOB, PCSK9 mutations), pathophysiology, and full treatment landscape including ezetimibe's mechanistic role
34480646	2021	Review	Current Cardiology Reports	Global burden and management of FH; emphasizes ezetimibe's role in achieving LDL-C targets in both heterozygous and homozygous patients in line with recent guideline recommendations
37762244	2023	Review	Int J Mol Sci	Postprandial hyperlipidemia pathophysiology and treatments; discusses ezetimibe's effect on postprandial lipemia, particularly relevant for mixed dyslipidemia patients
40682836	2025	Review	Molecular Medicine Reports	Current drug targets for hyperlipidemia including ezetimibe; covers NPC1L1-mediated mechanism and its positioning alongside statins, PCSK9 inhibitors, and bempedoic acid
35593194	2022	Review	J Cardiovasc Pharmacol Ther	Comprehensive PCSK9 inhibitor review; positions ezetimibe as the standard bridge therapy for statin-intolerant and inadequately controlled hypercholesterolemia patients
18376001	2008	Editorial	N Engl J Med	Landmark NEJM editorial on cholesterol lowering and ezetimibe following early ENHANCE controversy; pivotal in shaping clinical interpretation of ezetimibe's LDL-C vs. outcomes data

Taiwan Market Information

Ezetimibe is currently not registered in Taiwan (台灣未上市; TFDA authorization count: 0). No approved product licenses or package inserts are available from the TFDA database at this time.

For reference, Ezetimibe is approved and commercially available in numerous major regulatory jurisdictions under the following product names:

Jurisdiction	Brand Name	Dosage Form
USA (FDA)	Zetia®	10 mg oral tablet
USA/Global (FDA/EMA)	Vytorin® (ezetimibe/simvastatin FDC)	10/10, 10/20, 10/40, 10/80 mg tablets
EU/Global (EMA)	Ezetrol®	10 mg oral tablet
Japan (PMDA)	Zetia® (ゼチーア)	10 mg oral tablet
Korea	Ezetrol®	10 mg oral tablet

These approvals cover primary hypercholesterolemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence base for Ezetimibe in hyperlipoproteinemia is exceptionally strong (L1: multiple completed Phase 3 RCTs, international guideline endorsement, decades of post-marketing real-world data), and the TxGNN prediction score of 99.63% aligns with the drug's well-established clinical role; the primary barrier to use in Taiwan is the absence of TFDA registration rather than any scientific uncertainty about efficacy or safety.

To proceed, the following is needed:

TFDA regulatory filing: Initiate Taiwan new drug registration referencing existing FDA and EMA approvals; cross-reference Phase 3 data from NCT00093899, NCT00552097, and NCT03884452 as core submission evidence
Taiwan-bridging pharmacokinetics: Determine whether TFDA requires a bridging PK study in Taiwanese patients or accepts reference country data equivalence
Package insert (仿單) preparation: Compile complete TFDA-format warnings, contraindications, drug interaction profile (particularly cyclosporine, fibrates, and colesevelam interactions), and special population guidance (hepatic impairment, pregnancy)
Formal MOA documentation: Provide structured NPC1L1 mechanistic summary for TFDA scientific review dossier
Safety monitoring plan: Establish protocol for liver function tests, myopathy surveillance (especially with concomitant statin), and post-marketing pharmacovigilance in the Taiwan population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.